Total Payments
$48,455
2024 Payments
$1,670
Companies
12
Transactions
196
Payment Breakdown by Category
Research$20,368 (42.0%)
Travel$20,091 (41.5%)
Food & Beverage$7,976 (16.5%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,368 | 42 | 42.0% |
| Travel and Lodging | $20,091 | 68 | 41.5% |
| Food and Beverage | $7,976 | 85 | 16.5% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
General
$28,087
154 transactions
Research
$20,368
42 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $18,359 | 74 | $0 (2024) |
| Novo Nordisk AS | $17,982 | 62 | $0 (2022) |
| PFIZER INC. | $4,647 | 18 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $2,893 | 16 | $0 (2021) |
| Zealand Pharma A/S | $1,570 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,244 | 9 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,054 | 7 | $0 (2017) |
| Amgen Inc. | $307.77 | 3 | $0 (2018) |
| Novo Nordisk Inc | $204.69 | 2 | $0 (2022) |
| AbbVie, Inc. | $84.09 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,670 | 3 | Zealand Pharma A/S ($1,570) |
| 2023 | $825.21 | 4 | Eli Lilly and Company ($825.21) |
| 2022 | $6,467 | 21 | Novo Nordisk AS ($5,589) |
| 2021 | $73.84 | 2 | AstraZeneca Pharmaceuticals LP ($53.84) |
| 2020 | $6,524 | 8 | Eli Lilly and Company ($6,524) |
| 2019 | $18,058 | 94 | Eli Lilly and Company ($8,194) |
| 2018 | $6,325 | 30 | Eli Lilly and Company ($1,944) |
| 2017 | $8,513 | 34 | Novo Nordisk AS ($4,804) |
All Payment Transactions
196 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/03/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $1,300.46 | General |
| 11/03/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $270.00 | General |
| 09/10/2024 | Eli Lilly and Company | — | — | In-kind items and services | $99.20 | Research |
| Study: A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | ||||||
| 05/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $99.34 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | ||||||
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $195.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $332.51 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $198.36 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 09/14/2022 | Novo Nordisk AS | — | — | In-kind items and services | $772.49 | Research |
| 09/14/2022 | Novo Nordisk AS | — | — | In-kind items and services | $500.00 | Research |
| 09/14/2022 | Novo Nordisk AS | — | — | In-kind items and services | $401.40 | Research |
| 09/14/2022 | Novo Nordisk AS | — | — | In-kind items and services | $95.00 | Research |
| 09/14/2022 | Novo Nordisk AS | — | — | In-kind items and services | $68.75 | Research |
| 09/14/2022 | Novo Nordisk AS | — | — | In-kind items and services | $23.00 | Research |
| 08/22/2022 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $105.14 | General |
| 05/13/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $125.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/12/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $291.56 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $794.20 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $592.74 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $199.05 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $123.50 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $50.98 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $30.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $475.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $298.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 04/06/2022 | Novo Nordisk AS | Ozempic (Drug) | — | In-kind items and services | $145.00 | Research |
| Study: NN9535-4352 • Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $8,399 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $2,750 | 1 |
| EX9924-4473 | Novo Nordisk AS | $2,207 | 8 |
| NN9535-4352 | Novo Nordisk AS | $1,521 | 4 |
| A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | GlaxoSmithKline, LLC. | $1,054 | 7 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $611.10 | 3 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $332.51 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $298.00 | 1 |
| A PHASE 1A 1B STUDY OF LY3321367, AN ANTI-TIM-3 ANTIBODY, ADMINISTERED ALONE OR IN COMBINATION WITH LY3300054, AN ANTI-PD L1 ANTIBODY, IN ADVANCED RELAPSED REFRACTORY SOLID TUMORS | Eli Lilly and Company | $270.00 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $264.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $198.36 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $195.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $150.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $99.34 | 1 |
| A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | Eli Lilly and Company | $99.20 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $58.00 | 1 |
About Dr. Alexander Murray, M.D
Dr. Alexander Murray, M.D is a Family Medicine healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164557864.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander Murray, M.D has received a total of $48,455 in payments from pharmaceutical and medical device companies, with $1,670 received in 2024. These payments were reported across 196 transactions from 12 companies. The most common payment nature is "" ($20,368).
Ad
Practice Information
- Specialty Family Medicine
- Location Greensboro, NC
- Active Since 02/22/2007
- Last Updated 05/28/2013
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1164557864
Products in Payments
- Ozempic (Drug) $3,285
- Saxenda (Drug) $2,607
- Rybelsus (Drug) $2,207
- BEVESPI AEROSPHERE (Drug) $1,452
- COSENTYX (Biological) $1,244
- PREVNAR - 13 (Biological) $1,214
- Tresiba (Drug) $913.83
- Aimovig (Biological) $120.00
- Prolia (Biological) $120.00
- Creon (Drug) $84.09
- Repatha (Biological) $67.77
- INVOKANA (Drug) $59.00
- FARXIGA (Drug) $53.84
- JARDIANCE (Drug) $49.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Greensboro
Mrs. Veita Bland, M.d, M.D
Family Medicine — Payments: $53,051
Family Medicine $53,051
Dr. Robert Cowles, M.d, M.D
Family Medicine — Payments: $31,631
Family Medicine $31,631
Dr. John Lalonde, M.d, M.D
Family Medicine — Payments: $16,294
Family Medicine $16,294
Dana Collins, D.o, D.O
Family Medicine — Payments: $12,715
Family Medicine $12,715
Dr. Brent Greenberg, M.d, M.D
Family Medicine — Payments: $10,958
Family Medicine $10,958
Karen Richter, Md, MD
Family Medicine — Payments: $10,875
Family Medicine $10,875